ArticlePloS one2025
Time to phlebitis onsite and its predictors among admitted patients with peripheral intravenous cannulas at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia, 2024/ 2025: A prospective follow-up study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPhlebitis due to peripheral intravenous cannulation is a common issue in hospitalized patients which leading to serious complications such as deep vein and pulmonary thromboembolism, and septicemia. Understanding the time to phlebitis onset and its predictors is of clinical importance. However, data on its incidence, contributing factors, and time of onset remain limited in Ethiopia. Given the scarcity of compressive studies conducted in Ethiopia and the critical knowledge gap on the incidence, predictors, and timing of phlebitis onset, this study is significant in advancing clinical practice by identifying the time to onset of phlebitis and its predictors among hospitalized patients with peripheral intravenous cannulation.
methodA prospective follow-up study design was conducted on a sample size of 372 participants using structured interviews and observational checklists. Time to phlebitis onset was determined with the Kaplan-Meier method and log-log plots, while predictors were identified using Cox proportional hazards regression.
resultThe cumulative incidence of phlebitis was 39.25% (95% CI: 34.25%-44.41%), with a median onset time of 5 days (IQR 4-6 days). Whereas, the significant predictors were female sex (AHR = 1.58, 95% CI: 1.11-2.25), use of an 18-gauge cannula (AHR = 2.02, 95% CI: 1.20-3.41), receipt of a blood transfusion (AHR = 2.11, 95% CI: 1.14-3.91), and administration of potassium chloride (AHR = 1.93, 95% CI: 1.17-3.19) and vancomycin (AHR = 2.89, 95% CI: 1.73-4.83).
conclusionIn this study, the incidence of peripheral intravenous cannula-induced phlebitis was high, with a lower median time of phlebitis onset. The key predictors were female sex, large cannula, receipt of a blood transfusion, and administration of potassium chloride and vancomycin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.